Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | $2,996 | $1,702 | $4,315 | $2,787 |
| Research and development | 100,754 | 91,940 | 181,902 | 164,683 |
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
| Loss from operations | (110,552) | (127,056) | (220,577) | (233,685) |
| Interest income, net | 9,730 | 14,513 | 20,525 | 30,600 |
| Other income, net | 119 | 523 | 238 | 1,776 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's SG&A?
- Agios Pharmaceuticals (AGIO) reported SG&A of $51.55M in Q2 2026.
- How has Agios Pharmaceuticals's SG&A changed year-over-year?
- Agios Pharmaceuticals's SG&A increased by 12.4% year-over-year, from $45.87M to $51.55M.
- What is the long-term trend for Agios Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's SG&A has grown at a 10.4% compound annual growth rate (CAGR), from $121.45M to $180.28M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Agios Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude